Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30152392 | 0.98 | IRAK4 (0.57) | IRAK4HTTHSD11B1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL31474423 | 0.98 | IRAK4 (0.57) | IRAK4HTTHSD11B1SMN1; SMN2NPC1 | |
| SCHEMBL10042194 | 0.86 | HTT (0.58) | IRAK4HTTHSD11B1SMN1; SMN2NPC1 | |
| SCHEMBL946897 | 0.86 | IRAK4 (0.68) | IRAK4HTTHSD11B1SMN1; SMN2NPC1 | |
| SCHEMBL309358 | 0.86 | HSD11B1 (0.57) | IRAK4HTTHSD11B1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL19030927 | 0.84 | HSD11B1 (0.56) | IRAK4HTTHSD11B1SMN1; SMN2NPC1 | |
| SCHEMBL10554596 | 0.84 | IRAK4 (0.57) | IRAK4HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL23807849 | 0.84 | SMPD3 (0.53) | IRAK4HTTHSD11B1SMN1; SMN2NPC1 | |
| SCHEMBL30798522 | 0.83 | HTT (0.63) | IRAK4HTTHSD11B1SMN1; SMN2NPC1 | |
| SCHEMBL20347030 | 0.82 | IRAK4 (0.52) | IRAK4HTTHSD11B1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | claimed |
| US-20260146044-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | INCRELAND (CN) | 2026-05-28 | — | — | US | disclosed |
| EP-4746966-A1 | 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2026-05-27 | — | — | EP | disclosed |
| EP-4745142-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Increland (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4725946-A1 | IRAK4 DEGRADATION AGENT AND USE THEREOF | Guangzhou Unirise Pharmaceutical Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-4847256-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0264773-A1 | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
| EP-0244166-A2 | Heterocyclic acetyl sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146044-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | IRAK4, IRAK2, IRAK1 | IRAK4 1/4885HTT 2156/4885HSD11B1 727/4885 |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | IRAK4 480/4885HTT 2091/4885HSD11B1 3822/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | IRAK4 2233/4885HTT 3651/4885HSD11B1 86/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | IRAK4 3/4885HTT 4417/4885HSD11B1 1060/4885 |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | IRAK4 79/4885HTT 4830/4885HSD11B1 492/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | IRAK4 403/4885HTT 4719/4885HSD11B1 2295/4885 |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | TYMP, DPYD, TYMS | IRAK4 3593/4885HTT 2314/4885HSD11B1 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.